一年的癌症疫苗成功实践指明了前进的道路。
A year of successful cancer vaccines points to a path forward.
作者信息
Morse Michael A, Whelan Michael
机构信息
Duke University Medical Center, Durham, NC 27710, USA.
出版信息
Curr Opin Mol Ther. 2010 Feb;12(1):11-3.
PMID:20140811
Abstract
Results from recent clinical trials of the therapeutic vaccines sipuleucel-T (Dendreon Corp), PROSTVAC-VF-TRICOM (National Cancer Institute/BN ImmunoTherapeutics Inc) and BiovaxID (Biovest International Inc) are highlighted. These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer.
摘要
近期针对治疗性疫苗sipuleucel-T（丹德昂公司）、PROSTVAC-VF-TRICOM（美国国立癌症研究所/BN免疫治疗公司）和BiovaxID（百维斯国际公司）的临床试验结果得到了重点介绍。这些数据支持此类疫苗的进一步研发，并为开发改良药物以及制定使用治疗性疫苗治疗癌症的方案提供了指导。
Zotero 插件